UK speeds up medical device innovation with faster MHRA approvals and AI focus

The UK's Medicines and Healthcare products Regulatory Agency (MHRA) is speeding up medical device innovation with faster approvals and stronger support for researchers. Over the past year, the agency has hit every statutory deadline for clinical investigations, while cutting red tape for cutting-edge technologies like AI and neurotech.

More companies are now choosing Britain to test advanced medical tools, drawn by quicker processes and specialist guidance in high-demand fields such as dementia and Parkinson's disease.

Since September 2023, the MHRA has approved all clinical investigation applications on time, with an average decision period of 51 days. This efficiency has helped push a 17% increase in approved studies compared to the previous year. The agency's focus remains on balancing speed with patient safety, ensuring innovative ideas move forward without unnecessary delays.

To support complex technologies, the MHRA has expanded its specialist advice meetings. These now cover areas like neurotechnology, cardiac devices, surgical robotics, and AI. One key example is the agency's role in a UK-wide partnership to update national guidance on neurotech research. The aim is to simplify and accelerate studies involving brain-interactive devices, a field seeing rapid growth due to conditions like dementia, Parkinson's, and epilepsy—where research has doubled since 2024.

AI-powered medical devices are also surging, with tools now capable of scanning images for early disease detection, guiding treatment choices, and tailoring patient care. To further boost innovation, the MHRA will introduce a fee waiver pilot from January 2026, targeting micro and small UK firms. The agency's hands-on scientific support, including study design advice, has consistently received high marks from researchers.

The push comes as global competition intensifies to develop solutions for challenging health conditions. By reducing barriers and offering targeted expertise, the MHRA is positioning the UK as a leading destination for medical device testing and development.

The MHRA's measures—faster approvals, expanded specialist advice, and fee waivers—are already drawing more clinical investigations to the UK. With neurotech and AI studies on the rise, the agency's updated guidance and support frameworks aim to keep Britain at the forefront of medical innovation. The next phase includes rolling out further incentives to sustain this growth in 2026 and beyond.